Angelo Gardellini

Learn More
The modern concept of personalized medicine acknowledges the ancient teaching ‘first do no harm’ by delivering the minimum efficacious rather than the maximum tolerable treatment. Along this line, a diagnostic procedure should be well-tolerated and associated with very low morbidity, besides sensitive, accurate, reproducible and cost-effective. As a(More)
PURPOSE Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limited published data supporting the clinical equivalence in(More)
Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low dose (10 mg three times per week, for 18 weeks) to 49 patients with pre-treated CLL. The overall response rate was 53%, including 27% of complete(More)
References 1. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, et al. Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004;55:97–112. 2. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315–9. 3. Baggerly KA, Morris JS, Coombes KR. Reproducibility of(More)
Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Current evidence suggests that the addition of plerixafor with chemotherapy plus G-CSF is(More)
Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma. We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ⩾ 2 × 10(6) CD34+cells/kg, 80% of(More)
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapeutic option for many malignant and nonmalignant hematologic disorders. Despite this, several factors unfavorably affect the outcome of this procedure and in particular chronic graft-versus-host disease (cGVHD) remains the principal cause of morbidity after allogeneic(More)
Dear Editor, Concerning the letter to the editor by Piccin et al. [1], we would like to report the experience of the Haematoncology Division of European Institute of Oncology. We recently observed two patients treated with radioimmunotherapy (RIT; 90Y-DOTATOC/Lu177-DOTATOC) because of the presence of neuroendrocrine tumours. The first patient was a male of(More)
  • 1